Apr-13 -

Genito-Urinary Group

EORTC 30985 – Intermittent androgen deprivation in patients with stage D2 prostate cancer-Phase III.

EORTC’s follow-up study of over 13 years in patients treated for metastatic hormone-sensitive prostate cancer, found that intermittent androgen deprivation does not improve overall survival compared to continuous treatment.


Go to Top